Refine
Year of publication
Document Type
- Preprint (508)
- Article (318)
- Working Paper (3)
Has Fulltext
- yes (829)
Is part of the Bibliography
- no (829)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (5)
- Quark-Gluon Plasma (4)
- Atmospheric chemistry (3)
- Jets and Jet Substructure (3)
- Acute myeloid leukemia (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Induction chemotherapy (2)
- Intensive care treatment (2)
- LHC (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Survival (2)
- habit formation (2)
- 900 GeV (1)
- ALICE (1)
- ALICE detector (1)
- ALK (1)
- AML (1)
- ASCT (1)
- Acute kidney failure (1)
- Analysis and statistical methods (1)
- Anti-nuclei (1)
- Atomic and Molecular Physics (1)
- BEZ235 (1)
- Biogeochemistry (1)
- Biomarkers (1)
- Bone marrow aspiration (1)
- Brain tumor (1)
- CBC (1)
- CHIP (1)
- COMP (1)
- COVID 19 (1)
- COVID-19 (1)
- CVID (1)
- Calorimeters (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Centrality Class (1)
- Centrality Selection (1)
- Chemistry (1)
- Climate-change impacts (1)
- Collective Flow (1)
- Consumption hump (1)
- Data processing methods (1)
- Ecotoxicology (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Environmental quality (1)
- European Society for Immunodeficiencies (ESID) (1)
- Fibre/foam sandwich radiator (1)
- Fluid overload (1)
- German PID-NET registry (1)
- Glioma (1)
- Hadron-Hadron Scattering (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Hypertension (1)
- IgG substitution therapy (1)
- Immunology (1)
- Inflammation (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jets (1)
- Litter (1)
- MMPs (1)
- MRI (1)
- Marine chemistry (1)
- Microplastics (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molecular matched therapy (1)
- Molecular profiling (1)
- Monitoring (1)
- Monte Carlo (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Neural network (1)
- Oncology (1)
- PI3K/mTor inhibition (1)
- PID prevalence (1)
- PYTHIA (1)
- Palaeoceanography (1)
- Palaeoclimate (1)
- Particle Correlations and Fluctuations (1)
- Pb–Pb collisions (1)
- Performance of High Energy Physics Detectors (1)
- Peripheral blood smears (1)
- Phase I clinical trial (1)
- Pinus sylvestris (1)
- Plastics (1)
- Polymers (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proteins (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- RET (1)
- ROS1 (1)
- Rapidity Range (1)
- Refractory ALL (1)
- Refractory AML (1)
- Relapse surveillance (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Review (1)
- SARS CoV 2 (1)
- SARS-CoV-2 (1)
- Systematic Uncertainty (1)
- TR (1)
- Targeted therapy (1)
- Thermodynamics (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Vector Boson Production (1)
- Water framework directive (1)
- Xenon-based gas mixture (1)
- autologous stem cell transplantation (1)
- binary nucleation (1)
- cBioPortal (1)
- cartilage (1)
- chemotherapy (1)
- clinical (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- computational biology (1)
- computer-assisted (1)
- consumption hump (1)
- cortical malformation (1)
- cortical thickness (1)
- dE/dx (1)
- decision making (1)
- decision support systems (1)
- double inversion recovery (DIR) (1)
- focal cortical dysplasia (FCD) (1)
- forest dynamics (1)
- fusion kinase (1)
- glioblastoma (1)
- gray‐white matter blurring (1)
- heavy ion experiments (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- housing expenditure share (1)
- human capital (1)
- hypoxia (1)
- impatience (1)
- ion‐induced nucleation (1)
- leukemia (1)
- life-cycle household decisions (1)
- life-cycle utility maximization (1)
- lung cancer (1)
- mass spectrometry-based proteomics (1)
- molecular tumor board (1)
- neoplasms (1)
- neutralizing antibodies (1)
- osteoarthritis (1)
- patterns of progression (1)
- perioperative ischemia (1)
- permanent observation plots (1)
- phosphoproteomics (1)
- precision medicine (1)
- primary immunodeficiency (PID) (1)
- protein–protein interactions (1)
- quantitative T1 mapping (1)
- quark gluon plasma (1)
- registry for primary immunodeficiency (1)
- renting vs. owning home (1)
- requirements analysis (1)
- somatic mutations (1)
- spatial interactions (1)
- spike protein (1)
- stock market participation (1)
- thrombospondins (1)
- transient interactions (1)
- variants of concern (1)
Institute
- Physik (788)
- Frankfurt Institute for Advanced Studies (FIAS) (727)
- Informatik (693)
- Medizin (20)
- Geowissenschaften (13)
- Center for Financial Studies (CFS) (3)
- House of Finance (HoF) (3)
- Informatik und Mathematik (3)
- Wirtschaftswissenschaften (3)
- Biowissenschaften (2)
We set up and solve a rich life-cycle model of household decisions involving consumption of both perishable goods and housing services, stochastic and unspanned labor income, stochastic house prices, home renting and owning, stock investments, and portfolio constraints. The model features habit formation for housing consumption, which leads to optimal decisions closer in line with empirical observations. Our model can explain (i) that stock investments are low or zero for many young agents and then gradually increasing over life, (ii) that the housing expenditure share is age- and wealth-dependent, (iii) that perishable consumption is more sensitive to wealth and income shocks than housing consumption, and (iv) that non-housing consumption is hump-shaped over life.
We show that the optimal consumption of an individual over the life cycle can have the hump shape (inverted U-shape) observed empirically if the preferences of the individual exhibit internal habit formation. In the absence of habit formation, an impatient individual would prefer a decreasing consumption path over life. However, because of habit formation, a high initial consumption would lead to high required consumption in the future. To cover the future required consumption, wealth is set aside, but the necessary amount decreases with age which allows consumption to increase in the early part of life. At some age, the impatience outweighs the habit concerns so that consumption starts to decrease. We derive the optimal consumption strategy in closed form, deduce sufficient conditions for the presence of a consumption hump, and characterize the age at which the hump occurs. Numerical examples illustrate our findings. We show that our model calibrates well to U.S. consumption data from the Consumer Expenditure Survey.
Background: Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient treatment for acute leukemia. The primary objective of this phase I single center open label study was to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the dual pan-class I PI3K and mTOR inhibitor BEZ235 in patients with advanced leukemia.
Methods: Herein patients > 18 years of age who had relapsed or showed refractory leukemia were treated with BEZ235 (orally at 300–400 mg BID (cohort − 1/1)) to assess safety, tolerability, preliminary efficacy and pharmacokinetic (PK). Adverse events data and serious adverse events were analyzed and haematological and clinical biochemistry toxicities were assessed from laboratory test parameters. Response was assessed for the first time at the end of cycle 1 (day 29) and after every subsequent cycle. Pharmacokinetic and pharmacodynamic analyses of BEZ235 were also included (BEZ235 plasma levels, phosphorylation of AKT, S6 and 4EBP1). On statistics this trial is a multiple ascending dose study in which a following variant of the 3 + 3 rule (“Rolling Six”), a minimum of 6 and a maximum of 12 patients was recruited for the dose escalation and another 5 were planned for the expansion phase.
Results: Twenty-four patients with ALL (n = 11) or AML (n = 12) or CML-BP (n = 1) were enrolled. All patients had failed one (n = 5) or more lines of therapy (n = 5) and 14 patients were in refractory / refractory relapse. No formal MTD was defined, stomatitis and gastrointestinal toxicity at 400 mg BID dose was considered incompatible with prolonged treatment. The RP2D of BEZ235 was defined as 300 mg BID. Four of 24 patients showed clinical benefit. Twenty-two of 24 patients discontinued because of progression, (median time to progression 27 days (4d-112d). There was no association between PK parameters and efficacy or tolerability.
Conclusions: Combined inhibition of PI3K and mTOR inhibits a clinically meaningful driver pathway in a small subset of patients with ALL, with no benefit in patients with AML.
Trial registration: ClinicalTrials.gov, identifier NCT01756118. retrospectively registered 19th December 2012, https://clinicaltrials.gov/ct2/show/NCT01756118.
A central motivation for the development of x-ray free-electron lasers has been the prospect of time-resolved single-molecule imaging with atomic resolution. Here, we show that x-ray photoelectron diffraction—where a photoelectron emitted after x-ray absorption illuminates the molecular structure from within—can be used to image the increase of the internuclear distance during the x-ray-induced fragmentation of an O2 molecule. By measuring the molecular-frame photoelectron emission patterns for a two-photon sequential K-shell ionization in coincidence with the fragment ions, and by sorting the data as a function of the measured kinetic energy release, we can resolve the elongation of the molecular bond by approximately 1.2 a.u. within the duration of the x-ray pulse. The experiment paves the road toward time-resolved pump-probe photoelectron diffraction imaging at high-repetition-rate x-ray free-electron lasers.
Matrix metalloproteinases (MMPs) play crucial roles in tissue homeostasis and pathologies by remodeling the extracellular matrix. Previous studies have demonstrated the biological activities of MMP-derived cleavage products. Furthermore, specific fragments can serve as biomarkers. Therefore, an in vitro cleavage assay to identify substrates and characterize cleavage patterns could provide important insight in disease-relevant mechanisms and the identification of novel biomarkers. In the pathogenesis of osteoarthritis (OA), MMP-2, -8, -9 and -13 are of vital importance. However, it is unclear which protease can cleave which matrix component. To address this question, we established an in vitro cleavage assay using recombinantly expressed MMPs and the two cartilage matrix components, COMP and thrombospondin-4. We found a time- and concentration-dependent degradation and an MMP-specific cleavage pattern for both proteins. Cleavage products can now be enriched and purified to investigate their biological activity. To verify the in vivo relevance, we compared the in vitro cleavage patterns with serum and synovial fluid from OA patients and could indeed detect fragments of similar size in the human samples. The cleavage assay can be adapted to other MMPs and substrates, making it a valuable tool for many research fields.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.
The nucleosynthesis of elements beyond iron is dominated by neutron captures in the s and r processes. However, 32 stable, proton-rich isotopes cannot be formed during those processes, because they are shielded from the s-process flow and r-process β-decay chains. These nuclei are attributed to the p and rp process.
For all those processes, current research in nuclear astrophysics addresses the need for more precise reaction data involving radioactive isotopes. Depending on the particular reaction, direct or inverse kinematics, forward or time-reversed direction are investigated to determine or at least to constrain the desired reaction cross sections.
The Facility for Antiproton and Ion Research (FAIR) will offer unique, unprecedented opportunities to investigate many of the important reactions. The high yield of radioactive isotopes, even far away from the valley of stability, allows the investigation of isotopes involved in processes as exotic as the r or rp processes.